A Phase I, Dose-Escalating Study of the Safety of Intravenous CALAA-01 in Adults With Solid Tumors Refractory to Standard-of-Care Therapies.
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2013
At a glance
- Drugs CALAA 01 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 31 Aug 2012 Planned end date changed from 1 Sep 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 31 Aug 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.